PharmaLogic Strengthens Footing in Radiopharmaceutical Field with Acquisition
The radiopharmaceuticals CDMO will have a majority stake in Agilera Pharma, advancing its strategy of becoming a fully-integrated service provider in the radiopharmaceutical therapy sector.
Florida-based specialist radiopharmaceuticals CDMO, PharmaLogic, announced that it is acquiring a majority stake in experienced large-scale radiotherapeutics’ production company, Agilera Pharma, which is a subsidiary of the Institute for Energy Technology (IFE) in Norway, for an undisclosed sum (1). This investment will help PharmaLogics move forward with its strategy of becoming a fully-integrated, global CDMO that specializes in radiopharmaceutical therapies.
“PharmaLogic’s acquisition of Agilera, one of only two CDMOs worldwide currently manufacturing radiopharmaceutical therapeutics, accelerates the expansion of our capabilities in this high-growth field,” said Etienne Montagut, president of PharmaLogic, in a company press release about the deal (1). “By combining our expertise with Agilera’s industry-leading scale and quality systems, we will be uniquely positioned to offer an end-to-end solution for manufacturing therapeutics at scale and ultimately improve global patient access to these essential treatments. We’re thrilled to welcome Agilera’s very talented team to PharmaLogic and to take the lead in expanding our presence in Europe.”
Agilera has manufactured commercial radiopharmaceutical therapies throughout the U.S., Europe, and Asia, and has delivered over 600,000 commercial therapeutic doses to over 40 countries. Under the terms of the acquisition agreement, PharmaLogic will commit to invest in the expansion of Agilera’s CDMO capabilities, strengthening its infrastructure, and scaling its manufacturing footprint in order to meet the growing demand for radiopharmaceutical therapeutics.
“At Agilera, we highly welcome PharmaLogic as a majority shareholder in the company. Agilera's most important asset is the experience and expertise of our employees, as the company with the longest experience in large-scale production of radiotherapeutics globally. With PharmaLogic as a new owner beside IFE, this will enable further investments in the business to ensure that we have the right, available capacity to take on new customer projects and thus achieve faster adaptation to the promising market opportunities,” said Erik Flatmark, CEO of Agilera, in the press release (1). “An important step will be to strengthen European and transatlantic distribution of the products from both companies. We feel confident that we together will provide great opportunities for European, U.S., and global customers, with increased manufacturing capacity and capability in the market.”
“For IFE, the sale of a majority stake in Agilera marks a significant achievement as the largest commercialization effort carried out from the Institute to date,” added Nils Morten Huseby, CEO of IFE, in the press release (1). “As a leading Research Institute, IFE is committed to innovation and job creation and has played a key role in the development and manufacturing of radiopharmaceutical therapeutics through Agilera. The entry of PharmaLogic as a new majority shareholder in Agilera will enable rapid scale-up, growth and development of Agilera’s operations to meet the increased demand for radiopharmaceutical therapeutics globally.”
The radiopharmaceuticals market is expected to experience growth at a compound annual rate of 7.53%, reaching a value of USD 14.44 billion by 2034 (2). Drivers for this growth include technology advancements, increasing prevalence of chronic illnesses, the aging population, and the promising personalized medicine sector. However, the market is also facing several impeding factors, such as regulatory complexities and substantial upfront investment required to establish radiopharmaceutical production facilities.
References
PharmaLogic. PharmaLogic to Acquire Majority Stake in Agilera, Strengthening Global Expertise in Radiopharmaceuticals Therapeutics. Press Release, April 9, 2025.
Precedence Research. Radiopharmaceuticals Market Size, Share, and Trends 2025–2034. Market Research Report, March 13, 2025.